Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 1.00 |
| ▸ | MC3R | P41968 | 8/20 | 1.00 |
| ▸ | MC5R | P33032 | 7/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268528 | 1.00 | MC4R (1.00) | MC4RMC3RMC5R | |
| SCHEMBL14204839 | 1.00 | MC4R (1.00) | MC4RMC3RMC5R | |
| SCHEMBL14294628 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14270807 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14270802 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14294627 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14294630 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14270842 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14270810 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R | |
| SCHEMBL14270805 | 0.91 | MC4R (0.83) | MC4RMC3RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | claimed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | claimed |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-29 | — | — | US | claimed |
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MERCK & CO., INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | disclosed |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | NPY4R, GPR119, GIPR | MC4R 4/4885MC3R 9/4885MC5R 15/4885 |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | NPY5R, NPY4R, NPY2R | MC4R 9/4885MC3R 20/4885MC5R 5/4885 |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | MC4R 10/4885MC3R 67/4885MC5R 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.